Influence of body mass on predicted values of static hyperinflation in COPD od Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA

Dokumenty pełnotekstowe

COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany od Vogelmeier CF, Diesing J, Kossack N, Pignot M, Friedrich FW

Dokumenty pełnotekstowe

Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers od Alter P, Orszag J, Wouters EF, Vogelmeier CF, Jörres RA

Dokumenty pełnotekstowe

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population od Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K

Dokumenty pełnotekstowe

Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data od Stöber A, Lutter JI, Schwarzkopf L, Kirsch F, Schramm A, Vogelmeier CF, Leidl R

Dokumenty pełnotekstowe

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study od Buhl R, Criée C, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H

Dokumenty pełnotekstowe

Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis od Buhl R, Wilke T, Picker N, Schmidt O, Hechtner M, Kondla A, Maywald U, Vogelmeier CF

Dokumenty pełnotekstowe

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol od Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF

Dokumenty pełnotekstowe

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD od Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R

Dokumenty pełnotekstowe

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort od Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H

Dokumenty pełnotekstowe

The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis od Veith M, Tüffers J, Peychev E, Klemmer A, Kotke V, Janciauskiene S, Wilhelm S, Bals R, Koczulla AR, Vogelmeier CF, Greulich T

Dokumenty pełnotekstowe

Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study od Vogelmeier CF, Beeh KM, Schultze M, Kossack N, Richter LM, Claussen J, Compton C, Noorduyn SG, Ismaila AS, Requena G

Dokumenty pełnotekstowe

The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort od Wacker ME, Kitzing K, Jörres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R

Dokumenty pełnotekstowe

Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort od Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jörres RA

Dokumenty pełnotekstowe

Unravelling the Information Contained in the Single Items of the COPD Assessment Test for Different Outcomes and Smoking Status in Patients with COPD: Results from COSYCONET od Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Söhler S, Rabe KF, Wouters EFM, Vogelmeier CF, Jörres RA

Dokumenty pełnotekstowe

Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology od Veith M, Klemmer A, Anton I, El Hamss R, Rapun N, Janciauskiene S, Kotke V, Herr C, Bals R, Vogelmeier CF, Greulich T

Dokumenty pełnotekstowe

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of... od Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A

Dokumenty pełnotekstowe

Personalized medicine for patients with COPD: where are we? od Franssen FME, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, Maxheim M, Roessler FK, Spruit MA, Vogelmeier CF, Wouters EFM, Schmeck B

Dokumenty pełnotekstowe

Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET od Fischer C, Jörres RA, Alter P, Trudzinski FC, Yildirim, Bals R, Vogelmeier CF, Kauffmann-Guerrero D, Behr J, Watz H, Holle R, Kahnert K

Dokumenty pełnotekstowe

Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET od Kahnert K, Jörres RA, Lucke T, Trudzinski FC, Mertsch P, Bickert C, Ficker JH, Behr J, Bals R, Watz H, Welte T, Vogelmeier CF, Alter P

Dokumenty pełnotekstowe